Zacks Investment Research on MSN1d
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...
Business Wire10d
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.
Hosted on MSN3mon
Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?
QIAGEN N.V.’s QGEN solid potential in the molecular diagnostics area is poised to help it grow in the coming quarters.The company continues to progress with its test menu expansion, building a ...
EuropaWire6d
QIAGEN Gains FDA Approval for New QIAstat-Dx Gastrointestinal Panel 2 Mini B, Expanding Syndromic Testing Options
QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...
Nasdaq10d
QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology
(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind ...